What is Leerink Partnrs' Estimate for TMO Q1 Earnings?

Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) - Analysts at Leerink Partnrs issued their Q1 2026 earnings per share estimates for shares of Thermo Fisher Scientific in a research note issued to investors on Wednesday, April 23rd. Leerink Partnrs analyst P. Souda anticipates that the medical research company will earn $6.06 per share for the quarter. The consensus estimate for Thermo Fisher Scientific's current full-year earnings is $23.28 per share. Leerink Partnrs also issued estimates for Thermo Fisher Scientific's Q2 2026 earnings at $6.29 EPS, Q3 2026 earnings at $6.30 EPS, Q4 2026 earnings at $6.94 EPS and FY2026 earnings at $25.59 EPS.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $5.15 EPS for the quarter, beating analysts' consensus estimates of $5.10 by $0.05. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. The business had revenue of $10.36 billion for the quarter, compared to analysts' expectations of $10.23 billion. During the same period last year, the business earned $5.11 earnings per share. The business's quarterly revenue was up .2% on a year-over-year basis.

Other equities research analysts have also recently issued reports about the company. Citigroup dropped their target price on Thermo Fisher Scientific from $650.00 to $570.00 and set a "neutral" rating for the company in a report on Tuesday, March 4th. Raymond James restated an "outperform" rating and issued a $667.00 target price (up previously from $650.00) on shares of Thermo Fisher Scientific in a report on Monday, February 3rd. Morgan Stanley increased their price target on shares of Thermo Fisher Scientific from $647.00 to $678.00 and gave the company an "overweight" rating in a research report on Friday, January 31st. Stifel Nicolaus lowered their price objective on shares of Thermo Fisher Scientific from $665.00 to $620.00 and set a "buy" rating for the company in a research note on Thursday, April 24th. Finally, Royal Bank of Canada reduced their price target on Thermo Fisher Scientific from $651.00 to $637.00 and set an "outperform" rating on the stock in a report on Thursday, April 24th. Five investment analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $607.43.

Thermo Fisher Scientific Trading Up 1.4 %

Thermo Fisher Scientific stock traded up $6.01 during mid-day trading on Monday, hitting $425.90. The company's stock had a trading volume of 522,680 shares, compared to its average volume of 1,760,393. The stock has a market cap of $160.77 billion, a price-to-earnings ratio of 25.75, a price-to-earnings-growth ratio of 2.99 and a beta of 0.86. The business has a 50 day moving average price of $478.47 and a 200-day moving average price of $522.86. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.66 and a quick ratio of 1.29. Thermo Fisher Scientific has a 12 month low of $409.85 and a 12 month high of $627.88.

Hedge Funds Weigh In On Thermo Fisher Scientific

Several hedge funds have recently added to or reduced their stakes in the company. Howard Capital Management Group LLC boosted its stake in shares of Thermo Fisher Scientific by 0.5% during the third quarter. Howard Capital Management Group LLC now owns 54,575 shares of the medical research company's stock valued at $33,759,000 after purchasing an additional 286 shares during the period. Principal Financial Group Inc. boosted its holdings in shares of Thermo Fisher Scientific by 22.1% in the third quarter. Principal Financial Group Inc. now owns 1,247,838 shares of the medical research company's stock valued at $771,876,000 after purchasing an additional 225,568 shares during the period. Virtu Financial LLC bought a new stake in Thermo Fisher Scientific during the 3rd quarter valued at $638,000. Anchor Investment Management LLC grew its position in shares of Thermo Fisher Scientific by 1.7% during the 3rd quarter. Anchor Investment Management LLC now owns 11,366 shares of the medical research company's stock worth $7,031,000 after buying an additional 195 shares in the last quarter. Finally, World Investment Advisors LLC lifted its stake in Thermo Fisher Scientific by 3.8% in the third quarter. World Investment Advisors LLC now owns 15,088 shares of the medical research company's stock worth $9,333,000 after acquiring an additional 548 shares during the period. 89.23% of the stock is currently owned by institutional investors.

Insider Transactions at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the company's stock in a transaction that occurred on Tuesday, March 4th. The stock was sold at an average price of $516.67, for a total transaction of $5,166,700.00. Following the sale, the chief executive officer now directly owns 115,174 shares in the company, valued at $59,506,950.58. This represents a 7.99 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, EVP Gianluca Pettiti sold 300 shares of Thermo Fisher Scientific stock in a transaction on Tuesday, February 4th. The stock was sold at an average price of $585.59, for a total transaction of $175,677.00. Following the transaction, the executive vice president now directly owns 16,363 shares of the company's stock, valued at $9,582,009.17. The trade was a 1.80 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 24,200 shares of company stock valued at $13,235,041. 0.33% of the stock is currently owned by insiders.

Thermo Fisher Scientific Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, April 15th. Stockholders of record on Friday, March 14th were given a dividend of $0.43 per share. This is a positive change from Thermo Fisher Scientific's previous quarterly dividend of $0.39. The ex-dividend date of this dividend was Friday, March 14th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.40%. Thermo Fisher Scientific's dividend payout ratio (DPR) is presently 10.09%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.